Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: 15th International Conference on Human Retroviruses: HTLV and Related Viruses

Open Access Meeting abstract

Arsenic trioxyde in the treatment of HTLV1 associated ATLL

Felipe Suarez1*, Ambroise Marcais1, David Ghez2, Richard Delarue1, Benedicte Deau-Fischer1, Charbel Aoun1, Flore Sicre de Fontbrune1, Laurent Ysebaert3, Vahid Asnafi4, Daniele Canioni5, Hugue deThe6, Ali Bazarbachi7 and Olivier Hermine8*

Author Affiliations

1 Hématologie Adultes, Groupe Hospitalier Necker - Enfants malades, Paris, France

2 Hématologie Clinique, Institut Gustave Roussy, Villejuif, France

3 Hématologie, CHU Purpan, Toulouse, France

4 Hématologie Biologique, Groupe Hospitalier Necker - Enfants malades, Paris, France

5 Anatomie Pathologique, Groupe Hospitalier Necker - Enfants malades, Paris, France

6 CNRS Hôpital saint Louis, Paris , France

7 Hematology - Internal Medicine, American University Hospital, Beyrout, Liban

8 Hématologie Adultes et Cnrs Umr 8147, Groupe Hospitalier Necker - Enfants malades, Paris, France

For all author emails, please log on.

Retrovirology 2011, 8(Suppl 1):A59  doi:10.1186/1742-4690-8-S1-A59

The electronic version of this article is the complete one and can be found online at:

Published:6 June 2011

© 2011 Suarez et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The prognosis of Adult T-cell leukemia/lymphoma (ATLL) associated with HTLV1 is dismal. The response to conventional chemotherapy ranges between 20 and 70% and relaspe is constant. Median survival is 8 to 13 months. Chronic and smouldering ATLL have a longer survival, ranging from 18 to 72 months at 5 years. Interferon alpha (IFNa) and AZT combination therapy is effective in acute, chronic and smouldering ATLL, sometimes leading to complete response and has a better prognosis than conventional chemotherapy (5 year survival of 82% in acute and 100% in chronic and smouldering forms reaching a complete response). Patients with ATLL/lymphoma do not benefit from IFNa+AZT combination and despite initial response to chemotherapy, all patients eventually relapse. Arsenic trioxyde (AsO3) in combination with IFNa has in vitro activity with a negative regulation of the Tax oncoprotein and leads to apoptosis of HTLV1 transformed lymphocytes. A recent study has showed a benefit in chronic forms of ATLL.

Patients and methods

11 patients with ATLL were treated with AsO3+IFN combination after a minimum of 1 line of treatment.


3 patients had ATLL/lymphoma, 3 chronic and 5 acute. All patients had recieved previous therapy with chemotherapy associated or not with IFNa/AZT combination. At initiation of AsO3, 4 patients were in complete response (3 lymphoma, 1 acute), 2 partial response (1 acute, 1 chronic) et 5 in progression (3 acute, 2 chronic). 10 patients recieved AsO3 during 3 to 8 weeks 1 patient progressed 3 days after starting AsO3. Tolerance was acceptable with peripheral neurolopathy (n = 4), hand and foot syndrome (n = 3) et drug eruption (n = 3 including 2 toxic epidermal necrolysis). 6 patients died, and all were progressing at time of AsO3 initiation. 5 patients survived : 3 lymphomas in complete response (25, 31 et 46 months follow-up), 1 acute in complete response (9 months follow-up) and 1 one chronic in partial response (39 months follow-up).


AsO3 and IFNa combination has an acceptable tolerance profile and seems to be effective in ATLL in consolidation after response to a previous treatment, particularly in lymphoma and chronic forms.